The 25 mg tablet of Mirabegron extended-release (ER) is a medication used to treat overactive bladder (OAB) [1]. It is available under various brand names, including Myrbetriq and Betmiga [1].
How does Mirabegron ER 25 mg work?
Mirabegron ER 25 mg functions by relaxing the detrusor muscle in the bladder wall. This muscle is responsible for bladder contractions. By inhibiting the beta-3 adrenergic receptors, Mirabegron increases bladder capacity and reduces the involuntary contractions that lead to urgency, frequency, and incontinence associated with overactive bladder [2].
What is the typical dosage for Mirabegron ER 25 mg?
For the treatment of overactive bladder, the recommended starting dose for Mirabegron ER is 25 mg once daily [1]. The dosage may be increased to 50 mg once daily, depending on individual patient response and tolerability. It is important to take the tablet with liquid, without chewing, crushing, or breaking it [3].
What are the potential side effects of Mirabegron ER 25 mg?
Common side effects reported with Mirabegron ER include increased blood pressure, constipation, headache, nasopharyngitis, and urinary tract infection [2]. Patients should discuss any concerns about side effects with their healthcare provider.
When does the patent for Mirabegron expire?
The patent landscape for Mirabegron is complex, with multiple patents covering its composition of matter, methods of use, and formulations. Information on specific patent expiry dates can be found on specialized databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, which may include details on Mirabegron [4].
Are there generic versions of Mirabegron ER available?
As of now, generic versions of Mirabegron ER may be available in some markets, depending on patent expiry and regulatory approvals. The availability of generics can impact the cost of treatment.
How does Mirabegron ER compare to other OAB treatments?
Mirabegron ER offers an alternative mechanism of action compared to anticholinergic medications commonly used for OAB. While anticholinergics work by blocking muscarinic receptors, Mirabegron targets beta-3 adrenergic receptors. This difference in mechanism may lead to a different side effect profile, with Mirabegron generally not causing the dry mouth or constipation associated with anticholinergics [2].
What clinical data supports the use of Mirabegron ER 25 mg?
Clinical trials have demonstrated that Mirabegron ER 25 mg is effective in reducing the number of incontinence episodes and urgency episodes in patients with overactive bladder [2]. These studies have also assessed its safety profile in various patient populations.
Sources
1. Mirabegron Extended Release Tablets [Internet]. [cited 2023, October 26]. Available from: https://www.drugpatentwatch.com/drug/mirabegron-extended-release-tablets
2. Myrbetriq (mirabegron) prescribing information [Internet]. [cited 2023, October 26].
3. Betmiga 25 mg prolongat b. [Internet]. [cited 2023, October 26].
4. DrugPatentWatch.com [Internet]. [cited 2023, October 26]. Available from: https://www.drugpatentwatch.com/